|
|
|
|
Intron APR Newswire (press release), Psychiatric adverse events, which include insomnia, were common (57%) with PEG-INTRON, but similar to INTRON A (58%). Depression was most common at 29%. ... Older HCV Patients Have Tough Time with Combination Therapy Jan 9, 2006 MedPage Today, ...patients with chronic hepatitis C (HCV) infections are less likely than younger patients to tolerate combination therapy with Intron A (recombinant IFN alfa-2b ... Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in ... Jan 12, 2006 Yahoo! News (press release) There are no new adverse events specific to PEG-INTRON as compared to INTRON® A (interferon alfa-2b, recombinant) for Injection, however, the incidence of ... Schering-Plough Announces PEG-Intron and Rebetol Approved in Japan ... Dec 22, 2005 DG News There are no new adverse events specific to PEG-Intron as compared to Intron® A (interferon alfa-2b, recombinant) for Injection, however, the incidence of ... Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior ... Jan 4, 2006 PR Newswire (press release), Dr. Spicehandler played a major leadership role in the development and approval of several well-known drugs, including: (1) intron-A(R) (recombinant interferon ... Interferon with Ribavirin is safe and effective for children with ... Jan 1, 2006 Xagena.it, Nearly half of 118 children with chronic Hepatitis C virus ( HCV ) treated with a combination of Interferon-alpha-2b ( Intron A ) and an optimized dose of ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |